|
|
Post by mannmade on Jun 12, 2014 9:47:21 GMT -5
|
|
|
|
Post by kc on Jun 12, 2014 10:02:04 GMT -5
The Highlighted yellow portion I can't read. Just see the yellow. Can you cut and paste here.
|
|
|
|
Post by otherottawaguy on Jun 12, 2014 10:06:34 GMT -5
manmade:
Can't read the highlights, had to cut and past to notepad in order to read the following. Too bad there isn't a reference footnote avail.
OOG
New Insulins, Delivery Methods,
and Monitoring Technologies
Twonewultralong-actinginsulins,insulindegludecandLY2605541,
areundergoingtestinginphase3clinicaltrialsand,comparedwith
glargine, show similar efficacy but less hypoglycemia with daily in-
jections in patients with type 2 diabetes.
91-93
Technosphere insu-
lin, a new inhaled formulation, has been approved by the US Food
and Drug Administration.
Insulin is available in prefilled pens in which the dose is dialed
in and needles are changed between doses. These pens are being
used increasingly because of their convenience, greater accuracy,
andpatientpreference.
94
Theirmajorlimitationishigherpatientcost
andinsurancecoverage,althoughtotalannualizedhealthcostsmay
belowerandadherenceimproved.
95,96
Patientsin23of24studies
preferred pens to syringes, citing
ease of use, acceptability, conve-
nience, and perceived efficacy.
97
Continuousinsulininfusion(pump)therapyinpatientswithtype
2 diabetes can be considered in those with severe insulin resis-
tanceandpoorcontrol.
98,99
Newermechanicalpatchpumpsarecur-
rentlybeingtestedinrandomizedtrials.
99
Continuousglucosemoni-
toring has been recommended in patients with type 2 diabetes to
detect nocturnal hypoglycemia, increased insulin resistance in the
morning(dawnphenomenon),postprandialhyperglycemia,andhy-
poglycemic unawareness and can be used during major regimen
changes.
100
|
|
|
|
Post by mannmade on Jun 12, 2014 10:08:00 GMT -5
Thank you otherottawaguy...
|
|
|
|
Post by kc on Jun 12, 2014 10:10:57 GMT -5
don't jump the shark.......
I don't think this writer has it right or that the editor of the Journal proofed the article very well. Technosphere is not in a prefilled pen and there are no needles. This writer was confused. The Journal screwed it up royally by not editing the article.
Technosphere insu-
lin, a new inhaled formulation, has been approved by the US Food
and Drug Administration.
Insulin is available in prefilled pens in which the dose is dialed
in and needles are changed between doses. These pens are being
used increasingly because of their convenience, greater accuracy,
andpatientpreference.
Read more: mnkd.proboards.com/thread/883/ti-approved-fda-jama-ymb#ixzz34RD2frYn |
|
|
|
Post by ashiwi on Jun 12, 2014 10:11:45 GMT -5
Interesting find. Maybe this article wasn't supposed to come out this soon or the FDA spoke with the author.
Nice to see the words Technosphere inhaled insulin approved by the FDA.
|
|
|
|
Post by kc on Jun 12, 2014 10:18:34 GMT -5
Interesting find. Maybe this article wasn't supposed to come out this soon or the FDA spoke with the author. Nice to see the words Technosphere inhaled insulin approved by the FDA. Read above comment |
|
|
|
Post by mannmade on Jun 12, 2014 10:33:36 GMT -5
I tend to agree with kc however I must admit the timing is interesting and it may reflect pieces of various internal conversations... So is it a sign of things to come? Just more for us to discuss while we wait...
|
|
|
|
Post by kc on Jun 12, 2014 10:40:36 GMT -5
The timing of the article and this dates JAMA Journal was timed for the ADA convention. As the whole publication had multiple articles relating to Diabetes. I just think there was a serious proofing error.
Good things will come to all of us who beleive in MNKD. But not until at least July 15.
|
|
